Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Turner, Dan ^a   Zlotkin, Stanley H ^b   Shah, Prakeshkumar S ^c   Griffiths, Anne Marie ^b  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adult; Child; Crohn disease *diet therapy ; Fatty acids, omega 3 *therapeutic use ; Fish oils *therapeutic use ; Humans; Randomized controlled trials as topic; Recurrence prevention control ; Remission induction

Indexed keywords

ARACHIDONIC ACID; BUDESONIDE; CORTICOSTEROID; DOCOSAHEXANOIC ACID; EICOSAPENTOIC ACID; EPANOVA; FISH OIL; MESALAZINE; OLIVE OIL; OMEGA 3 FATTY ACID; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; BLEEDING TIME; BLOATING; CLINICAL TRIAL; COCHRANE LIBRARY; COMPUTER PROGRAM; CROHN DISEASE; DATA ANALYSIS; DATA EXTRACTION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; EMBASE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HALITOSIS; HEARTBURN; HUMAN; INFORMATION PROCESSING; INTERVENTION STUDY; MAINTENANCE THERAPY; MANTEL HAENSZEL TEST; MEDICAL EXPERT; MEDLINE; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PUBLISHING; QUALITY CONTROL; RECURRENCE RISK; REMISSION; REVIEW; SCIENTIFIC LITERATURE; SCORING SYSTEM; SIDE EFFECT; SYSTEMATIC REVIEW; TASTE DISORDER; VOMITING;

EID: 67649851124     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006320.pub3     Document Type: Review

References (59)

1. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334(24):1557-1560
2. Belluzzi A, Campieri M, Belloli C, Boschi S, Cottone M, Rizzello F, et al.A new enteric coated preparation of omega-3 fatty acids for preventing post-surgical recurrence in Crohn's disease. Gastroenterology 1997;112(4):A930.
3. * Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, et al.Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 2008;299(14):1690- 1697
4. Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, et al.Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 2008;299(14):1690-1697
5. Lorenz-Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig WE, et al.Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand J Gastroenterol 1996;31(8):778-785
6. Romano C, Cucchiara S, Barabino A, Annese V, Sferlazzas C.Usefulness of omega-3 fatty acid supplementation in addition tomesalazine inmaintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World J Gastroenterol 2005; 11(45):7118-21.
7. Lorenz R, Weber PC, Szimnau P, Heldwein W, Strasser T, Loeschke K. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease - a randomized, placebo-controlled, double- blind cross-over trial. J Intern Med Suppl 1989;731:225-232
8. Akabas SR, Deckelbaum RJ. Summary of a workshop on n-3 fatty acids: current status of recommendations and future directions. Am J Clin Nutr 2006;83(6 Suppl):1536S-8S.
9. Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 2006;83 (6 Suppl):1467S-76S.
10. Bamba T, Shimoyama T, Sasaki M, Tsujikawa T, Fukuda Y, Koganei K, et al. Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol 2003;15(2):151-157
11. Bassaganya-Riera J, Hontecillas R. CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. Clin Nutr 2006;25(3): 454-465
12. Belluzzi A, Brignola C, Campieri M, Camporesi EP, Gionchetti P, Rizzello F, et al.Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients. Dig Dis Sci 1994;39(12):2589- 2594
13. Belluzzi A. N-3 fatty acids for the treatment of inflammatory bowel diseases. Proc Nutr Soc 2002 Aug;61(3):391-395
14. Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70(3):439-444
15. Bjorkkjaer T, Brunborg LA, Arslan G, Lind RA, Brun JG, Valen M, et al.Reduced joint pain after short-term duodenal administration of seal oil in patients with inflammatory bowel disease: comparison with soy oil. Scand J Gastroenterol 2004;39(11):1088-1094
16. Clark HD, Wells GA, Huet C, McAlister FA, Salmi LR, Fergusson D, et al.Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials 1999;20(5):448-452
17. Deckelbaum RJ, Worgall TS, Seo T. N-3 fatty acids and gene expression. Am J Clin Nutr 2006;83(6 Suppl):1520S-5S.
18. Eivindson M, Gronbaek H, Nielsen JN, Frystyk J, Flyvbjerg A, Jorgensen L, et al.Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with omega-3 or omega-6 fatty acids and corticosteroids. Scand J Gastroenterol 2005;40(10): 1214-1221
19. el Boustani S, Colette C, Monnier L, Descomps B, Crastes de Paulet A, Mendy F. Enteral absorption in man of eicosapentaenoic acid in different chemical forms. Lipids 1987;22(10):711-714
20. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JW, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320 (5):265-271
21. Endres S, Lorenz R, Loeschke K. Lipid treatment of inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 1999;2(2):117-120
22. Ergas D, Eilat E, Mendlovic S, Sthoeger ZM. N-3 fatty acids and the immune system in autoimmunity. Isr Med Assoc J 2002;4(1):34-38
23. Figler M, Gasztonyi B, Cseh J, Horvath G, Kisbenedek AG, Bokor S, et al. Association of n-3 and n-6 long chain polyunsaturated fatty acids in plasma lipid classes with inflammatory bowel diseases. Br J Nutr 2007;97:1154-1161
24. Fisher M, Upchurch KS, Levine PH, Johnson MH, Vaudreuil CH, Natale A, et al. Effects of dietary fish oil supplementation on polymorphonuclear leukocyte inflammatory potential. Inflammation 1986; 10(4):387-392
25. Geerling BJ, Badart-Smook A, van Deursen C, van Houwelingen AC, Russel MG, Stockbrugger RW, et al.Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis 2000;6(2):77-84.
26. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1(8167):514.
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-560
28. Hillier K, Jewell R, Dorrell L, Smith CL. Incorporation of fatty acids fromfish oil and olive oil into colonicmucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 1991;32 (10):1151-1155
29. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H, Worthington HV, et al.Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database of Systematic Reviews 2004, Issue 4. [Art. No.: CD003177. DOI: 10.1002/14651858.CD003177.pub2]
30. Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;14(4):439-447
31. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996;17(1):1-12.
32. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323 (7303):42-46
33. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54(8):1121-1125
34. Kim YI. Can fish oil maintain Crohn's disease in remission?. Nutr Rev 1996 Aug;54(8):248-252
35. Kuroki F, Iida M, Matsumoto T, Aoyagi K, Kanamoto K, Fujishima M. Serum n3 polyunsaturated fatty acids are depleted in Crohn's disease. Dig Dis Sci 1997;42(6):1137-1141
36. Lawson LD, Hughes BG. Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters. Biochem Biophys Res Commun 1988;152(1):328-335
37. Lee TH, Hoover RL, Williams JD, Sperling RI, Ravalese J, 3rd, Spur BW, et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil andmonocyte leukotriene generation and neutrophil function. N Engl J Med 1985;312(19): 1217-1224
38. MacLean CH, Mojica WA, Newberry SJ, Pencharz J, Garland RH, Tu W, et al. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr 2005;82(3):611-619
39. Mate J, Castanos R, Garcia-Samaniego J, Pajares JM. Does dietary fish oilmaintain the remission of Crohn's disease (CD): A case control study. Gastroenterology 1991;100(5):A228.
40. Meister D, Ghosh S. Effect of fish oil enriched enteral diet on inflammatory bowel disease tissues in organ culture: differential effects on ulcerative colitis and Crohn's disease. World J Gastroenterol 2005; 11(47):7466-7472
41. Melanson SF, Lewandrowski EL, Flood JG, Lewandrowski KB. Measurement of organochlorines in commercial over-the-counter fish oil preparations: implications for dietary and therapeutic recommendations for omega-3 fatty acids and a review of the literature. Arch Pathol Lab Med 2005;129(1):74-77
42. Nakazawa A, Hibi T. Is fish oil (n-3 fatty acids) effective for the maintenance of remission in Crohn's disease?. J Gastroenterol 2000; 35(2):173-175
43. Nielsen AA, Jorgensen LG, Nielsen JN, Eivindson M, Gronbaek H, Vind I, et al. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids. Aliment Pharmacol Ther 2005;22(11-12): 1121-1128
44. Nieto N, Torres MI, Rios A, Gil A. Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis. J Nutr 2002;132(1):11-19
45. Oh R. Practical applications of fish oil (Omega-3 fatty acids) in primary care. J Am Board Fam Pract 2005;18(1):28-36.
46. Roy N, Barnett M, Knoch B, Dommels Y, McNabb W. Nutrigenomics applied to an animal model of Inflammatory Bowel Diseases: Transcriptomic analysis of the effects of eicosapentaenoic acid-and arachidonic acid-enriched diets. Mut Res 2007;622:103-116
47. Ruxton CH, Reed SC, Simpson MJ, Millington KJ. The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J Hum Nutr Diet 2004 Oct;17(5):449-459
48. Sakurai T, Matsui T, Yao T, Takagi Y, Hirai F, Aoyagi K, et al. Shortterm efficacy of enteral nutrition in the treatment of active Crohn's disease: a randomized, controlled trial comparing nutrient formulas. J Parenter Enteral Nutr 2002;26(2):98-103.
49. Seidman E, Bouthillier L, Thibault L, Lepage G, Chartre M, Deslandres C, et al.Clinical and nutritional parameters in Crohn's disease patients treated with either an n-3 PUFA-enriched semi-elemental or a polymeric diet. Results of a randomized controlled trial. J Pediatr Gastroenterol Nutr 2003;37(3):393.
50. Siguel EN, Lerman RH. Prevalence of essential fatty acid deficiency in patients with chronic gastrointestinal disorders. Metabolism 1996; 45(1):12-23.
51. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002;21(6):495-505.
52. Socha P, Ryzko J, Koletzko B, Czubkowski P, Korszynska D, Celinska-Cedro D, et al. The influence of fish oil therapy in children with inflammatory bowel disease on the fatty acid status. Pediatria Wspolczesna 2002;4(3):413-416
53. Socha P, Ryzko J, Koletzko B, Celinska-Cedro D, Woynarowski M, Czubkowski P, et al. Essential fatty acid depletion in children with inflammatory bowel disease. Scand J Gastroenterol 2005;40(5):573-577
54. Thayu M, Markowitz JE, Mamula P, Russo PA, Muinos WI, Baldassano RN. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005;40(2):220-222
55. Trebble TM, Arden NK, Wootton SA, Calder PC, Mullee MA, Fine DR, et al. Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. Am J Clin Nutr 2004;80(5):1137-1144
56. Trebble TM. Bone turnover and nutritional status in Crohn's disease: relationship to circulating mononuclear cell function and response to fish oil and antioxidants. Proc Nutr Soc 2005;64(2):183-191
57. Vilaseca J, Salas A, Guarner F, Rodriguez R, Martinez M, Malagelada JR. Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. Gut 1990;31(5): 539-544
58. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2007, Issue 1. [Art. No.: CD000542. DOI: 10.1002/14651858.CD000542.pub2]
59. Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2007, Issue 2. [Art. No.: CD006320. DOI: 10.1002/14651858. CD006320.pub2; MEDLINE: CD006320]